Skip to content

Depression: all studies

Page 478 of 1,036: studies 4,771 to 4,780 of 10,358, newest first. Back to the depression overview

Research

Inducing Psychedelic-Like States Through Brain Stimulation: A Review of Mechanisms, Clinical Evidence, and Psychotherapeutic Implications

BJPsych Open June 1, 2026 Sunandan Banerjee

Aims: To examine whether psychedelic-like states of consciousness can be induced through brain stimulation techniques, evaluate their potential advantages over pharmacological psychedelics, and explore how stimulation-assisted psychotherapy may offer a clinically viable model for mental health treatment. Methods: A structured narrative review was conducted using PubMed and PsycINFO,examining...

Effectiveness of meditation in the management of epilepsy: An updated mini systematic review of recent findings.

Complementary Therapies in Medicine June 1, 2026 Moirangthem Joychand Singh, Sunil Singh Yadav, Sangeeth Somanadhapai et al.

Epilepsy is a chronic neurological disorder characterized by altered cortical excitability. The disorder is often associated with psychological distress and reduced quality of life. The purpose of the present review is to critically summarize the evidence on the effectiveness of meditation-based interventions for people with epilepsy. A comprehensive search was conducted in PubMed, Scopus, and...

Self-treatment of psychiatric conditions using ketamine: Patterns, characteristics, and retrospective insights.

Journal of Psychopharmacology June 1, 2026 Gabrielle Smith, Timothy Piatkowski, Jason Ferris et al. 1 citation

While research on novel therapeutic applications of ketamine is expanding, particularly in controlled settings, there is limited exploration of its consumption related to self-treatment of psychiatric conditions. This study investigated the characteristics of people who use ketamine and psychedelics for self-treatment of psychiatric conditions, providing insight into patterns of use within this...

Rapid antidepressant potential of nitrous oxide: current state and major questions.

Molecular Psychiatry June 1, 2026 Charles F Zorumski, Joseph Cichon, Yukitoshi Izumi et al. 5 citations

The success of ketamine, a dissociative anesthetic and non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist, as a rapidly acting antidepressant has ignited efforts to identify other novel depression treatments. In recent years, several clinical trials indicated that nitrous oxide (N2O), an inhalational dissociative anesthetic in clinical use for over 150 years, also has rapid and...

General Anesthesia and Discrete Components of Ketamine Neurophysiology.

JAMA Psychiatry June 1, 2026 Ben Deverett, Duan Li, Theresa R. Lii et al. 1 citation

Ketamine has well-known dissociative, analgesic, and antidepressant properties, but it is unknown whether the neurophysiologic effects that are associated with these properties can be modulated separately from one another. Considering that specific cortical oscillations have been associated with specific therapeutic effects, modulating selective aspects of ketamine neurophysiology could inform...

Transcriptional profiles of antidepressant resistance across the corticolimbic pathway of chronically stressed mice.

Neuropsychopharmacology June 1, 2026 Trevonn M Gyles, Eric M Parise, Molly S Estill et al.

Treatment-resistant depression (TRD), defined by unsuccessful response to multiple antidepressants, affects approximately one-third of individuals with major depressive disorder, yet its underlying molecular mechanisms remain poorly understood. Here, we developed a preclinical model of TRD in which mice exposed to chronic social defeat stress were sequentially treated with fluoxetine (FLX) and...

Differential effects of ketamine enantiomers on EEG parameters including the gamma-delta shift phenomenon.

British Journal of Pharmacology June 1, 2026 Szabolcs Koncz, Dóra Pothorszki, Noémi Papp et al. 2 citations

Ketamine consists of two enantiomers, (R)-ketamine and (S)-ketamine, which exhibit distinct pharmacological properties. Currently, only the (S)-enantiomer has been approved for the treatment of major depressive disorder, whereas recent clinical studies have failed to demonstrate an antidepressant effect for (R)-ketamine. The quantitative electroencephalography (qEEG) gamma-enhancing effect of...

Electroconvulsive Therapy Versus Ketamine for Major Depressive Episode

BJPsych Open June 1, 2026 James Finlay

Aims: To review and compare the safety, efficacy, cost-effectiveness and remission rates of electroconvulsive therapy (ECT) versus ketamine in patients with major depressive episodes. Methods: A narrative review of the literature was undertaken, focusing on randomised and non-randomised clinical trials, systematic reviews, and meta-analyses comparing ketamine and ECT in adults with major...

Adolescent ketamine exposure impairs spike timing-dependent plasticity and GABAergic transmission in pyramidal neurons of the mouse prefrontal cortex.

The Journal of Physiology June 1, 2026 Felipe Guiffa-Gómez, Sashá Van Buuren, Freddy Aguilar et al. 1 citation

The medial prefrontal cortex (mPFC) undergoes extensive GABAergic interneuron maturation during adolescence, a process that establishes excitatory-inhibitory balance and supports adult cognitive function. Disruptions during this critical developmental period contribute to neuropsychiatric disorders, yet the enduring consequences for adult synaptic plasticity remain poorly understood. Here we...

An Update on Somatic Treatments for Suicide Risk.

American Journal of Psychiatry June 1, 2026 Mina M Rizk, J John Mann 1 citation

Suicide is a major cause of death worldwide and a key public health challenge. Pharmacologic and neuromodulatory interventions are central to suicide prevention. This review summarizes evidence for these interventions with potential antisuicidal effects across major psychiatric disorders and, where possible, distinguishes their direct effects on suicide diathesis from those mediated by...